Detalhe da pesquisa
1.
Differential expression of the immunosuppressive enzyme IL4I1 in human induced Aiolos+, but not natural Helios+, FOXP3+ Treg cells.
Eur J Immunol
; 45(2): 474-9, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25446972
2.
Human memory Helios- FOXP3+ regulatory T cells (Tregs) encompass induced Tregs that express Aiolos and respond to IL-1ß by downregulating their suppressor functions.
J Immunol
; 191(9): 4619-27, 2013 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24068664
3.
MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer.
Haematologica
; 98(2): 316-22, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22875619
4.
Ex vivo IL-1 receptor type I expression in human CD4+ T cells identifies an early intermediate in the differentiation of Th17 from FOXP3+ naive regulatory T cells.
J Immunol
; 187(10): 5196-202, 2011 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21998454
5.
Human RORγt+ TH17 cells preferentially differentiate from naive FOXP3+Treg in the presence of lineage-specific polarizing factors.
Proc Natl Acad Sci U S A
; 107(45): 19402-7, 2010 Nov 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-20962281
6.
Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers.
Proc Natl Acad Sci U S A
; 107(16): 7437-42, 2010 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-20368442
7.
Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t.
Proc Natl Acad Sci U S A
; 106(21): 8635-40, 2009 May 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-19439651
8.
Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma.
Clin Cancer Res
; 28(12): 2555-2566, 2022 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35421231
9.
Comment on "differentiation of IL-17-producing effector and regulatory human T cells from lineage-committed naive precursors".
J Immunol
; 193(7): 3181, 2014 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25240015
10.
Thymic selection generates a large T cell pool recognizing a self-peptide in humans.
J Exp Med
; 195(4): 485-94, 2002 Feb 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-11854361
11.
Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans.
J Exp Med
; 196(2): 207-16, 2002 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12119345
12.
Comment on "helios+ and helios- cells coexist within the natural FOXP3+ T regulatory cell subset in humans".
J Immunol
; 190(9): 4439-40, 2013 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23606718
13.
HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine.
Clin Cancer Res
; 15(1): 299-306, 2009 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19118058
14.
IL-1beta and IL-2 convert human Treg into T(H)17 cells.
Clin Immunol
; 131(2): 298-307, 2009 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-19211307
15.
Generation of Th17 from human naive CD4+ T cells preferentially occurs from FOXP3+ Tregs upon costimulation via CD28 or CD5.
Blood
; 119(20): 4810-2; author reply 4812-3, 2012 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-22596172
16.
Cross-presentation of NY-ESO-1 cytotoxic T lymphocyte epitope fused to human heat shock cognate protein 70 by dendritic cells.
Cancer Sci
; 99(1): 107-12, 2008 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17991294
17.
A peripheral circulating compartment of natural naive CD4 Tregs.
J Clin Invest
; 115(7): 1953-62, 2005 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16007258
18.
Processing of tumor-associated antigen by the proteasomes of dendritic cells controls in vivo T-cell responses.
Cancer Res
; 66(10): 5461-8, 2006 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16707475
19.
An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR.
J Clin Invest
; 113(8): 1225-33, 2004 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-15085202
20.
Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting.
J Clin Invest
; 110(12): 1813-22, 2002 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-12488431